Skip to main content

Table 3 Multivariate analysis for LFS, OS, RI, NRM, and cGVHD

From: Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

 

HR

95% CI

p value

LFS

 UD vs MSD

0.96

0.79

1.17

0.68

 Age ≥50 years

1.17

0.98

1.40

0.09

 Year of Tx > median

1.02

0.85

1.23

0.83

 Cytogenetics

  Poor vs intermediate

1.61

1.24

2.09

<10−3

  Missing vs intermediate

1.18

0.96

1.46

0.11

 CMV patient positive

1.19

0.98

1.44

0.09

 CMV donor positive

0.99

0.82

1.19

0.90

 Female to male

1.03

0.84

1.26

0.77

 Diag to Tx > median

1.21

1.02

1.44

0.03

 KPS > 90%

0.67

0.56

0.80

<10−5

 In vivo T depletion

1.02

0.84

1.26

0.81

 Conditioning regimen (ref = MAC)

  RIC vs MAC

0.89

0.73

1.08

0.25

  Sequential strategy vs MAC

0.91

0.69

1.21

0.53

OS

 UD vs MSD

1.02

0.83

1.25

0.87

 Age ≥50 years

1.33

1.10

1.61

0.004

 Year of Tx > median

1.02

0.84

1.24

0.83

 Cytogenetics

  Poor vs intermediate

1.55

1.19

2.03

0.001

  Missing vs intermediate

1.23

0.99

1.53

0.06

 CMV patient positive

1.28

1.04

1.58

0.02

 CMV donor positive

0.97

0.80

1.19

0.79

 Female to male

1.06

0.86

1.32

0.57

 Diag to Tx > median

1.20

1.00

1.44

0.05

 KPS >90%

0.65

0.54

0.79

<10−5

 In vivo T depletion

0.94

0.76

1.16

0.55

 Conditioning regimen (ref = MAC)

  RIC vs MAC

0.83

0.67

1.02

0.08

  Sequential strategy vs MAC

0.81

0.60

1.09

1.16

RI

 UD vs MSD

0.89

0.71

1.12

0.33

 Age ≥50 years

0.99

0.80

1.22

0.94

 Year of Tx >median

0.95

0.77

1.18

0.66

 Cytogenetics

  Poor vs intermediate

1.74

1.30

2.33

<10−3

  Missing vs intermediate

1.10

0.86

1.40

0.45

 CMV patient positive

1.07

0.86

1.33

0.56

 CMV donor positive

0.97

0.78

1.20

0.75

 Female to male

1.08

0.86

1.37

0.51

 Diag to Tx > median

1.29

1.06

1.58

0.01

 KPS >90%

0.77

0.62

0.95

0.01

 In vivo T depletion

1.10

0.87

1.40

0.43

 Conditioning regimen (ref = MAC)

  RIC vs MAC

1.03

0.81

1.29

0.83

  Sequential strategy vs MAC

0.98

0.71

1.35

0.89

NRM

 UD vs MSD

1.30

0.91

1.86

0.14

 Age ≥50 years

1.77

1.27

2.47

0.001

 Year of Tx > median

1.18

0.84

1.64

0.33

 Cytogenetics

  Poor vs intermediate

1.53

0.91

2.59

0.11

  Missing vs intermediate

1.44

0.98

2.13

0.06

 CMV patient positive

1.68

1.14

2.47

0.01

 CMV donor positive

1.06

0.75

1.49

0.76

 Female to male

1.01

0.70

1.47

0.95

 Diag to Tx > median

1.06

0.77

1.45

0.72

 KPS >90%

0.48

0.35

0.66

<10−5

 In vivo T depletion

0.89

0.62

1.29

0.54

 Conditioning regimen (ref = MAC)

  RIC vs MAC

0.59

0.41

0.85

0.005

  Sequential strategy vs MAC

0.82

0.48

1.38

0.45

cGVHD

 UD vs MSD

1.22

0.86

1.74

0.26

 Age ≥50 years

1.06

0.76

1.47

0.73

 Year of Tx > median

1.06

0.76

1.48

0.72

 Cytogenetics

  Poor vs intermediate

1.01

0.64

1.59

0.96

  Missing vs intermediate

0.82

0.58

1.16

0.26

 CMV patient positive

1.24

0.87

1.75

0.23

 CMV donor positive

1.07

0.76

1.51

0.70

 Female to male

1.53

1.07

2.19

0.02

 Diag to Tx > median

0.85

0.62

1.17

0.32

 KPS >90%

1.01

0.72

1.41

0.97

 In vivo T depletion

0.51

0.35

0.74

0.001

 Conditioning regimen (ref = MAC)

  RIC vs MAC

1.20

0.83

1.73

0.32

  Sequential strategy vs MAC

1.07

0.63

1.80

0.81

  1. Abbreviations: CI confidence interval, Diag diagnosis, GVHD graft-vs-host disease, HR hazard ratio, KPS Karnofsky Performance Status, LFS leukemia-free survival, MAC myeloablative conditioning, MSD matched sibling donor, NRM non-relapse mortality, OS overall survival, RIC reduced intensity conditioning, Tx transplantation, UD unrelated donor